Multiple Myeloma Experience Survey - Talquetamab + daratumumab combinations (Tal-D and Tal-DP) |
Introduction
We need your help!
Myeloma Canada is seeking information from people affected by multiple myeloma regarding two new treatment combinations soon undergoing reimbursement review:
- Talquetamab-daratumumab-pomalidomide (Tal-DP); and
- Talquetamab-daratumumab (Tal-D)
Sharing your experience can help decision-makers better understand how talquetamab treatment could benefit Canadians with myeloma.
This survey is intended for:
This survey is intended for:
- Adults living with relapsed/refractory multiple myeloma and their care partners who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor
OR
- Patients who have received or are currently receiving treatment with Tal-DP or Tal-D and their care partners.
This survey should only take around 10 minutes of your time. We ask that the survey please be completed by November 16, 2026, 11:59 PM EST.
If you have any questions, please write to contact@myeloma.ca and indicate “Tal. Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.
If you have any questions, please write to contact@myeloma.ca and indicate “Tal. Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.